Vivek Subbiah Shannon N Westin Kai Wang Dejka Araujo Wei-Lien Wang Vincent A Miller Jeffrey S Ross Phillip J Stephens Gary A Palmer Siraj M Ali
10.1186/1756-8722-7-8
J Hematol Oncol
2014 Jan 14;7:8.
CC BY
https://pubmed.ncbi.nlm.nih.gov/24422672/
Antineoplastic Combined Chemotherapy Protocols / therapeutic use Molecular Targeted Therapy / methods Oncogene Proteins, Fusion / antagonists & inhibitors Proto-Oncogene Proteins B-raf / antagonists & inhibitors Sarcoma / drug therapy TOR Serine-Threonine Kinases / antagonists & inhibitors
Antineoplastic Combined Chemotherapy Protocols / therapeutic use Molecular Targeted Therapy / methods Oncogene Proteins, Fusion / antagonists & inhibitors Proto-Oncogene Proteins B-raf / antagonists & inhibitors Sarcoma / drug therapy TOR Serine-Threonine Kinases / antagonists & inhibitors Case Reports Clinical Trial, Phase I Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Antibodies, Monoclonal, Humanized / administration & dosage Antigens, CD34 / metabolism Bevacizumab Female Humans Immunohistochemistry Middle Aged Niacinamide / administration & dosage Niacinamide / analogs & derivatives Oncogene Proteins, Fusion / genetics Phenylurea Compounds / administration & dosage Proto-Oncogene Proteins B-raf / metabolism S100 Proteins / metabolism Sarcoma / genetics Sarcoma / metabolism Sequence Analysis, DNA Sirolimus / administration & dosage Sirolimus / analogs & derivatives Sorafenib TOR Serine-Threonine Kinases / metabolism Treatment Outcome Antibodies, Monoclonal, Humanized Antigens, CD34 BRAF-KIAA1549 fusion protein, human Oncogene Proteins, Fusion Phenylurea Compounds S100 Proteins Niacinamide Bevacizumab temsirolimus Sorafenib MTOR protein, human Proto-Oncogene Proteins B-raf TOR Serine-Threonine Kinases Sirolimus
PMC3896681
24422672
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
2014